Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Acute Lymphocytic Leukemia Drug Market by Type (Oral, Parenteral), By Application (Application I, Application II) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Acute Lymphocytic Leukemia Drug Market by Type (Oral, Parenteral), By Application (Application I, Application II) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 132083 3300 Pharma & Healthcare 377 234 Pages 4.6 (36)
                                          

The global acute lymphocytic leukemia drug market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing incidence of acute lymphocytic leukemia and the rising awareness about its treatment. The oral drugs segment is expected to dominate the global acute lymphocytic leukemia drug market during the forecast period, owing to their ease of administration and low cost. The North American region accounted for a major share in terms of revenue in 2017, followed by Europe and Asia Pacific respectively. This trend is likely to continue over the next few years as well due to high prevalence rates in these regions. -The number of new cases of Acute Lymphocytic Leukemia is expected to increase by 1.5% annually, from about 20,000 in 2010 to about 22,000 in 2020. -The number of deaths from Acute Lymphocytic Leukemia is expected to increase by 1.5% annually, from about 10,000 in 2010 to about 11,500 in 2020. -Acute Lymphocytic Leukemia drug market growth factors are the increasing incidence and prevalence rates for Acute Lymphocytic Leukemia and the availability of new drugs for treatment.

Industry Growth Insights published a new data on “Acute Lymphocytic Leukemia Drug Market”. The research report is titled “Acute Lymphocytic Leukemia Drug Market research by Types (Oral, Parenteral), By Applications (Application I, Application II), By Players/Companies Amgen, Bristol-Myers Squibb, Novartis, Ariad, Arno Therapeutics, Baxter, Boehringer Ingelheim, ERYTECH Pharma, Fate Therapeutics, Jazz Pharmaceuticals, Orphan Europe, Otsuka, Ono Pharmaceuticals, Onconova Therapeutics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sigma-Tau Pharmaceuticals”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Acute Lymphocytic Leukemia Drug Market Research Report

By Type

Oral, Parenteral

By Application

Application I, Application II

By Companies

Amgen, Bristol-Myers Squibb, Novartis, Ariad, Arno Therapeutics, Baxter, Boehringer Ingelheim, ERYTECH Pharma, Fate Therapeutics, Jazz Pharmaceuticals, Orphan Europe, Otsuka, Ono Pharmaceuticals, Onconova Therapeutics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sigma-Tau Pharmaceuticals

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

234

Number of Tables & Figures

164

Customization Available

Yes, the report can be customized as per your need.


Global Acute Lymphocytic Leukemia Drug Industry Outlook


Global Acute Lymphocytic Leukemia Drug Market Report Segments:

The global Acute Lymphocytic Leukemia Drug market is segmented on the basis of:

Types

Oral, Parenteral

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Application I, Application II

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Amgen
  2. Bristol-Myers Squibb
  3. Novartis
  4. Ariad
  5. Arno Therapeutics
  6. Baxter
  7. Boehringer Ingelheim
  8. ERYTECH Pharma
  9. Fate Therapeutics
  10. Jazz Pharmaceuticals
  11. Orphan Europe
  12. Otsuka
  13. Ono Pharmaceuticals
  14. Onconova Therapeutics
  15. Pfizer
  16. Regeneron Pharmaceuticals
  17. Sanofi
  18. Sigma-Tau Pharmaceuticals

Global Acute Lymphocytic Leukemia Drug Market Overview


Highlights of The Acute Lymphocytic Leukemia Drug Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Oral
    2. Parenteral
  1. By Application:

    1. Application I
    2. Application II
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Acute Lymphocytic Leukemia Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Acute Lymphocytic Leukemia Drug Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Acute lymphocytic leukemia (ALL) is a cancer of the white blood cells. Drugs used to treat ALL include chemotherapy and radiation therapy.

Some of the major companies in the acute lymphocytic leukemia drug market are Amgen, Bristol-Myers Squibb, Novartis, Ariad, Arno Therapeutics, Baxter, Boehringer Ingelheim, ERYTECH Pharma, Fate Therapeutics, Jazz Pharmaceuticals, Orphan Europe, Otsuka, Ono Pharmaceuticals, Onconova Therapeutics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sigma-Tau Pharmaceuticals.

The acute lymphocytic leukemia drug market is expected to register a CAGR of 5.5%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Acute Lymphocytic Leukemia Drug Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Acute Lymphocytic Leukemia Drug Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Acute Lymphocytic Leukemia Drug Market - Supply Chain
   4.5. Global Acute Lymphocytic Leukemia Drug Market Forecast
      4.5.1. Acute Lymphocytic Leukemia Drug Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Acute Lymphocytic Leukemia Drug Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Acute Lymphocytic Leukemia Drug Market Absolute $ Opportunity

5. Global Acute Lymphocytic Leukemia Drug Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by Type
      5.3.1. Oral
      5.3.2. Parenteral
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Acute Lymphocytic Leukemia Drug Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by ApplicationIII
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Acute Lymphocytic Leukemia Drug Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Acute Lymphocytic Leukemia Drug Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Acute Lymphocytic Leukemia Drug Demand Share Forecast, 2019-2029

9. North America Acute Lymphocytic Leukemia Drug Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by ApplicationIII
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by Type
      9.7.1. Oral
      9.7.2. Parenteral
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Acute Lymphocytic Leukemia Drug Demand Share Forecast, 2019-2029

10. Latin America Acute Lymphocytic Leukemia Drug Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by ApplicationIII
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by Type
      10.7.1. Oral
      10.7.2. Parenteral
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Acute Lymphocytic Leukemia Drug Demand Share Forecast, 2019-2029

11. Europe Acute Lymphocytic Leukemia Drug Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by ApplicationIII
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by Type
      11.7.1. Oral
      11.7.2. Parenteral
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growt Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Acute Lymphocytic Leukemia Drug Demand Share, 2019-2029

12. Asia Pacific Acute Lymphocytic Leukemia Drug Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by ApplicationIII
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by Type
      12.7.1. Oral
      12.7.2. Parenteral
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Acute Lymphocytic Leukemia Drug Demand Share, 2019-2029

13. Middle East & Africa Acute Lymphocytic Leukemia Drug Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by ApplicationIII
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Acute Lymphocytic Leukemia Drug Market Size and Volume Forecast by Type
      13.7.1. Oral
      13.7.2. Parenteral
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Acute Lymphocytic Leukemia Drug Demand Share, 2019-2029

14. Competition Landscape
   14.1. Global Acute Lymphocytic Leukemia Drug Market: Market Share Analysis
   14.2. Acute Lymphocytic Leukemia Drug Distributors and Customers
   14.3. Acute Lymphocytic Leukemia Drug Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Amgen
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Bristol-Myers Squibb
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Novartis
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Ariad
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Arno Therapeutics
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Baxter
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Boehringer Ingelheim
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. ERYTECH Pharma
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Fate Therapeutics
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Jazz Pharmaceuticals
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. Orphan Europe
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. Otsuka
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. Ono Pharmaceuticals
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. Onconova Therapeutics
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. Pfizer
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. Regeneron Pharmaceuticals
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. Sanofi
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. Sigma-Tau Pharmaceuticals
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us